Eli Lilly: Tirzepatide Lowers Risk Of Developing Type 2 Diabetes By 94% In 3-yr Study
20/8 13:09
(RTTNews) - Eli Lilly and Company (LLY) reported positive topline results from the SURMOUNT-1 three-year study evaluating the efficacy and safety of tirzepatide once weekly for long-term weight management and delay in progression to diabetes in adults with pre-diabetes and obesit...